News
ARWR ▲ +1.8% - Arrowhead Pharmaceuticals, Inc.
ARWR ▲ +1.8% - Arrowhead Pharmaceuticals, Inc.
$ARWR - Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia
07-OCT-2026 07:38 AM ET
Share this post
More filings for $ARWR
ARWR ▲ +2.0% - Arrowhead Pharmaceuticals, Inc.Oct 27, 2026ARWR ▲ +0.7% - Arrowhead Pharmaceuticals, Inc.Oct 15, 2026ARWR ▲ +3.0% - Arrowhead Pharmaceuticals, Inc.Oct 14, 2026ARWR ▲ +1.8% - Arrowhead Pharmaceuticals, Inc.Oct 7, 2026ARWR ▲ +0.4% - Arrowhead Pharmaceuticals, Inc.Sep 15, 2026ARWR ▼ -0.8% - Arrowhead Pharmaceuticals, Inc.Sep 3, 2026
View full $ARWR filing history →💬 Comments
Loading comments…
Leave a comment